Skip to main content

Bio-Path Holdings, Inc. (BPTH)

NASDAQ: BPTH · IEX Real-Time Price · USD
4.98
-0.06 (-1.19%)
After-hours:Oct 22, 2021 7:37 PM EDT
5.04
-0.20 (-3.82%)
At close: Oct 22, 4:00 PM
Market Cap35.39M
Revenue (ttm)n/a
Net Income (ttm)-9.77M
Shares Out6.96M
EPS (ttm)-1.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume86,231
Open5.19
Previous Close5.24
Day's Range4.99 - 5.19
52-Week Range3.12 - 24.34
Beta1.92
AnalystsBuy
Price Target12.50 (+148.0%)
Est. Earnings DateNov 11, 2021

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also d...

IndustryBiotechnology
Founded2007
Employees10
Stock ExchangeNASDAQ
Ticker SymbolBPTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for BPTH stock is "Buy" and the 12-month stock price forecast is 12.50.

Price Target
$12.50
(148.02% upside)
Analyst Consensus: Buy

News

Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients.

1 month ago - Zacks Investment Research

BPTH Stock: The Good News That Has BioPath Investors Smiling Today

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today ap...

1 month ago - InvestorPlace

BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Tha...

1 month ago - InvestorPlace

Why Bio-Path Holdings Shares Are Surging Higher Today

Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 i...

1 month ago - Benzinga

Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?

The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b trial, si...

1 month ago - Benzinga

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute...

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Pro...

1 month ago - GlobeNewsWire

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

2 months ago - GlobeNewsWire

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf...

2 months ago - GlobeNewsWire

Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna...

Other symbols:MRNAVTVT
4 months ago - Benzinga

Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expressi...

4 months ago - GlobeNewsWire

Bio-Path Holdings Reports First Quarter 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

5 months ago - GlobeNewsWire

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfo...

5 months ago - GlobeNewsWire

Bio-Path Announces Publication in Biomedicines

Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug D...

6 months ago - GlobeNewsWire

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...

Other symbols:ACADCDTX
6 months ago - Benzinga

Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leuke...

Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapie...

6 months ago - Benzinga

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine...

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

6 months ago - GlobeNewsWire

Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade

Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

7 months ago - Zacks Investment Research

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop ...

7 months ago - GlobeNewsWire

Bio-Path Holdings Reports Full Year 2020 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

7 months ago - GlobeNewsWire

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

7 months ago - GlobeNewsWire

Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

8 months ago - GlobeNewsWire

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

8 months ago - GlobeNewsWire

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

8 months ago - GlobeNewsWire

Why Bio-Path's Stock Is Surging Higher Today

Bio-Path (NASDAQ: BPTH) shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Bio-Path Holdings Inc...

8 months ago - Benzinga

BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today

Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform. The post BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today appeared...

8 months ago - InvestorPlace